Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers

British Journal of Biomedical Science

Volumn 57, Issue 3, 2000, Pages 207-213

  Belgore, F M ^a   Lip, G Y H ^a   Blann, A D ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Angiogenesis factor; Growth factor; Receptors; Smoking; VEGF

Indexed keywords

BIOLOGICAL MARKER; THROMBOMODULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER; CELL ACTIVATION; CELL DAMAGE; CELL FUNCTION; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MOLECULE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING;

ADULT; AGED; CROSS-SECTIONAL STUDIES; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMAN; LYMPHOKINES; MALE; MIDDLE AGE; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SMOKING; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 0033796959     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Angiogenesis: Mechanistic insight, neovascular diseases, and therapeutic prospects
2. Vascular permeability factor/vascular endothelial growth, microvascular hyperpermeability, and angiogenesis
3. Enhancement of tumour growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells
4. Vascular permeability factor (VPF, VEGF) in tumour biology
5. Aortic smooth muscle cells express and secrete vascular endothelial growth factor
6. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascitic fluid
7. Isolation and chromosomal localisation of a novel FMS-like tyrosine kinase gene
8. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
9. Considering cellular thrombomodulin distribution and its modulating factors can facilitate the use of plasma thrombomodulin as a reliable endothelial marker
10. Thrombomodulin is a new biological and prognostic marker for breast cancer: An immunohistological study
11. Expression and localisation of thrombomodulin in pre-neoplastic bronchial lesions and in lung cancer
12. Anticoagulant effects of retinoic acids on leukaemic cells
13. Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumour tissue and cyst fluid: The key to angiogenesis
14. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumour-bearing mice and cancer patients
15. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR
16. Increased plasma thrombomodulin in cancer patients
17. Is thrombomodulin useful as a marker of a lung cancer?
18. Cytokines and thrombomodulin
19. Smoking
20. Influence of smoking on soluble adhesion molecules and endothelial cell markers
21. Diet, gender and plasma thrombomodulin
22. Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies on plasma
23. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) study: A case-cohort study
24. Smoking in pregnancy
25. Raised C-reactive protein levels in serum from smokers
26. Cardiovascular effects of nicotine: Relation to deleterious effects of cigarette smoking
27. Increased production of oxygen free radicals in cigarette smokers
28. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers
29. Inter-individual heterogeneity in the hypoxia regulation of VEGF: Significance for development of coronary artery collateral circulation
30. Characterisation of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase)
31. Vascular endothelial growth factor and its receptors
32. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor
33. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis and mortality rate
34. A vascular endothelial growth factor antagonist is produced by human placenta and released into maternal circulation
35. Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: Implications for measurement of circulating VEGF levels in clinical disease
36. Treatment of unstable angina